Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

doi:10.1182/bloodadvances.2021005066

Skip Nav Destination

ERRATUM| June 4, 2021

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1⁻ MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Blood Adv (2021) 5 (11): 2515.

https://doi.org/10.1182/bloodadvances.2021005066

In “Acknowledgments” on page 4756, National Heart, Lung, and Blood Institute grant T3HL147741 should not have been cited. The error has been corrected in the published article.

2021

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1⁻ MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1⁻ MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.